North America

Invitae reported $66.3 million in revenues for the fourth quarter, which fell short of the consensus Wall Street estimate of $68.1 million.

The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The company will conduct a clinical study examining the proteins BCL6 and SIRT1 as biomarkers of endometriosis and endometrial receptivity.

The company said its sample preparation technology uses nanomagnetic particles that can reduce the effects of complex interferences in patient samples.

The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.